Kornimate/medical-research-clean huggingface dataset:
18f-fdg-pet guided dose-painting with intensity modulated radiotherapy in oropharyngeal tumours

Conditions: Oropharyngeal Cancer

Summary: treatment of cancers of the head and neck, including oropharyngeal tumours, usually consist of a combination of radiotherapy and chemotherapy, although surgery may also play a part. radiotherapy works by using the high energy x-rays to destroy cancer cells. head and neck cancers often respond well to radiotherapy in the first instance and a proportion of patients will be cured by this treatment. however, not all of the cancer cells are destroyed by the combination of radiotherapy and chemotherapy and, in some patients, the cancer does come back. studies have suggested that more efficient killing of cancer cells, and therefore, better cure rates, can be achieved by increasing the radiotherapy dose. however, in the past, this was not possible due to side effects. intensity modulated radiotherapy (imrt) is a new radiotherapy delivery technique that allows better shaping of the dose to the areas that need irradiating with the potential for fewer side effects. if the investigators use imrt to deliver an intentionally higher dose of radiation (called a boost) to small selected areas whilst, at the same time giving standard treatment doses to the remaining areas, this approach is called imrt dose-painting. these selected areas can be identified by a scan called 18f-fdg-pet (18f-fluorodeoxyglucose-positron emission tomography, also known as a 'pet' scan) which is a type of scan that can give information about the activity of a cancer. the purpose of this study is to find out whether the investigators can use imrt dose-painting to boost the dose to the region inside a tumour which appears most active on 18f-fdg-pet. if this study shows that this approach is well-tolerated, then the investigators may be able to improve cure rates with this treatment. this would need to be tested in a subsequent study.


Eligibility criteria:
inclusion criteria: * histologically confirmed squamous cell carcinoma (scc) of the oropharynx assessed as either hpv negative or hpv positive with greater than 10 pack year smoking history and n stage at least n2b, to be treated with primary radical neoadjuvant chemotherapy followed by chemo-intensity modulated radiotherapy (chemo-imrt) to the primary and bilateral neck nodes * age ≥ 18 years. * ≥t2 tumours. * staging 18f-fdg-pet/ct showing adequate uptake at the level of the primary tumour. * who performance status 0-2. * renal function adequate for cisplatin chemotherapy. * all patients must be suitable to attend regular follow-up. * written informed consent must be obtained in all patients. exclusion criteria: * previous radiotherapy to the head and neck region interfering with the protocol treatment plan. * previous malignancy except non-melanoma skin cancer. * previous or concurrent illness, which in the investigators opinion, would interfere with either completion of therapy or follow-up.
bidirectional cohort study on improvement of quality of life in patients after coronary intervention with kuanxiong aerosol

Conditions: Angina Pectoris; Kuanzhong Aerosol; Quality of Life; Cardiac Function

Summary: the goal of this observational study is to compare in patients with angina pectoris after pci for coronary heart disease. the main questions it aims to answer are: * to evaluate the effect of kuanxiong aerosol on the quality of life of patients with angina pectoris after pci for coronary heart disease. * to evaluate the effect of kuanxiong aerosol on relieving angina pectoris and improving cardiac function. the comparison group will received routine treatment .the experimental group will received sublingual spray of kuanxiong aerosol on the basis of routine treatment，two sprays per time，three times a day, for a continuous month. after 1 month of treatment, the quality of life, the improvement of cardiac function and the relief of angina pectoris were compared between the two groups. researchers will compare two groups to see if kuanxiong aerosol can improve the quality of life, cardiac function, and reduce the frequency and duration of angina pectoris in patients with angina pectoris after pci.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for coronary heart disease * age 18\~80 years old, male and female, lower limbs can move freely * patients with coronary angiography or coronary ct angiography indicating that the rate of coronary artery large vessel stenosis is greater than 80% * patients with angina pectoris (angina pectoris frequency ≥3 times/week) after pci according to the judgment of the treating physician * according to the doctor\&#39;s judgment, patients who need to use conventional drugs (acei/arb, β-blockers), and patients who need to use kuanxiong aerosol drugs on the basis of conventional drug therapy * patients voluntarily sign informed consent exclusion criteria: * allergic to ingredients contained in kuanxiong aerosol * coronary artery bypass grafting was prepared during the trial * blood lipid and uric acid exceeding 1.5 times the upper limit of normal reference value; uncontrolled severe hypertension with systolic blood pressure \&gt;180mmhg and/or diastolic blood pressure \&gt;110mmhg * severe hepatic and renal insufficiency (alt, ast or tbil\&gt;1.5 times the upper limit of normal reference value, cr \&gt;1.5 times the upper limit of normal reference value) * malignant tumors * severe arrhythmias (such as rapid atrial fibrillation, ventricular tachycardia, high atrioventricular block, etc.) * women who are pregnant or trying to become pregnant * the researcher judged that it is not suitable to participate in this study

Keywords: quality of life kuanxiong aerosol angina pectoris cardiac function
hip socket erosion study

Conditions: Femoral Neck Fractures; Hemiarthroplasty; Acetabulum; Protrusion

Summary: the aim of this exploratory retrospective study is to gain a better understanding about the occurrence of acetabular erosion in patients after after hip hemiarthroplasty. the main objectives are i) to summarise a selection of basic patient characteristics of all patients of ≤ 75 years of age with a femoral neck fracture who have received either ha or tha, ii) to explore the proportion of patients after ha who developed acetabular erosion in the first years post-surgery and iii) to explore the proportion of patients after ha for whom acetabular erosion was the main reason for conversion surgery from ha to tha. a secondary objective is to assess the observer reliability of, and explore the association between, the baker classification grading and köhler line measurements. all participants approached for participation in the main phase of the study will be asked to give their written informed consent to use their patient data. patients who are willing to participate will also be asked to complete a short paper survey to collect data that is not available from their health records.

some orthopaedic surgeons believe that relatively 'young' older patients (aged ≤ 75 years) who have sustained a femoral neck fracture should be treated with hemiarthroplasty (ha) instead of total hip arthroplasty (tha). the rationale behind this belief is that tha is more time consuming, has greater associated surgical morbidity and may increase the risk of hip dislocation and subsequent revision surgery. on the other hand, ha is believed to accelerate acetabular erosion (i.e. wear) over time, which may ultimately lead to the need for conversion surgery from ha to tha. due to a lack of research in this area, it is unclear how often the development of acetabular erosion in patients after ha actually occurs. this makes it difficult for orthopaedic surgeons to make an informed choice between ha or tha surgery for this patient group. this is an exploratory retrospective study using existing electronic patient data of patients adhering to the inclusion criteria of the study, i.e. patients of ≤ 75 years of age who have had ha after a femoral neck fracture.

Eligibility criteria:
inclusion criteria: * having had a displaced femoral neck fracture that was subsequently treated with hemiarthroplasty * aged \< 75 years at the time of surgery * have at least two post-operative radiographs (with at least six weeks between them) available for acetabular erosion measurements. exclusion criteria: * patients diagnosed with rheumatoid arthritis, osteoporosis, hip dysplasia or a previous hip fracture of the ipsilateral hip.
efficacy of sbr759 in lowering serum phosphate levels in chronic kidney disease patients on hemodialysis

Conditions: Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

Summary: this study will evaluate the efficacy of sbr759 compared to sevelamer hcl in lowering serum phosphate levels in chronic kidney disease patients on hemodialysis


Eligibility criteria:
inclusion criteria * men or women of at least 18 years old. * stable maintenance of renal replacement therapy 3 times per week. * controlled serum phosphate if under phosphate-binder therapy. * serum phosphate level ≥ 6.0 mg/dl (\> 1.9 mmol/l) prior to study treatment initiation. exclusion criteria * peritoneal dialysis. * parathyroidectomy or transplant scheduled during the study. * uncontrolled hyperparathyroidism * history of hemochromatosis or ferritin \> 1000 µg/l. * clinically significant gi disorder * unstable medical condition other than chronic kidney disease. * treated with oral iron. * other protocol-defined inclusion/exclusion criteria may apply.

Keywords: chronic kidney disease hemodialysis hyperphosphatemia hemodiafiltration
opioid rotation from morphine to methadone in treatment of non-malignant pain

Conditions: Non-malignant Chronic Pain

Summary: patients with non-malignant pain are switched from morphine to methadone with a nine-months' follow-up.

twelve patients with poor pain control or unacceptable side effects during treatment with morphine were switched to methadone and followed for nine months in this open prospective study. primary outcomes were patient preference for opioid and pain control while physical, cognitive and role functioning were secondary outcomes. the morphine dose was decreased by 1/3 daily and was replaced with an equianalgesic dose of methadone over a three-day period. during switching and a one-week dose titration period, patients were given additional methadone if required. during dose titration one patient experienced sedation requiring naloxone. four patients were switched back to morphine due to poor pain control, drowsiness or sweating. seven patients preferred long-term (\>nine months) treatment with methadone and reported reduced pain and improved functioning while cognition was not improved. this study brings novel information on the long-term consequences for pain control, health-related quality of life and cognitive functioning with a switch from morphine to methadone in the treatment of chronic non-malignant pain.

Eligibility criteria:
inclusion criteria: * 18-70 years of age * non-malignant chronic pain * morphine use exclusion criteria: * addiction * kidney disorders
behavior of cyclists in response to pain

Conditions: Pain; Sport Injury; Athletic Injuries

Summary: a qualitative study, as a follow-up to an earlier study, that provides an opportunity to develop a deeper understanding of the injured cyclist's behavior related to seeking medical attention and endurance of pain. this study includes 10 club-level cyclists who have an injury and either have or have not sought medical attention.


Eligibility criteria:
inclusion criteria: * have at least one year of cycling experience and will not compete in multi-sport events such as a triathlon. * have had an injury currently or in the recent past associated with biking and experiencing pain related to cycling injury(s). * must read and speak english. exclusion criteria: * non-english speaking

Keywords: cycling endurance pain injury
a study to determine the safety, tolerability, pharmacokinetics, and preliminary efficacy of abbv-368 plus tilsotolimod and other therapy combinations in participants with recurrent/metastatic head and neck squamous cell carcinoma

Conditions: Advanced Solid Tumors Cancer

Summary: the main objective of this study is to assess safety, tolerability, and pharmacokinetics (pk) of abbv-368 plus tilsotolimod; abbv-368 plus tilsotolimod and nab-paclitaxel; and abbv-368 plus tilsotolimod, nab-paclitaxel, and abbv-181 in participants with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (hnscc).


Eligibility criteria:
inclusion criteria: * participants should weigh at least 35 kg. * eastern cooperative oncology group performance status of 0 or 1 and a life expectancy of \>= 3 months. * participant have \>= 1 lesion accessible for intratumoral injection. * histologically or cytologically confirmed r/m hnscc (of the following 4 subsites: oral cavity, oropharynx, larynx, and hypopharynx) who previously progressed either during or after \<= 3 prior treatment regimens administered in the recurrent or metastatic setting. * must have received 1 immunotherapy regimen which included a pd-(l)1 inhibitor. * must have received platinum-based therapy, or be considered ineligible for platinum-based therapy by the investigator. exclusion criteria: * uncontrolled metastases to the central nervous system (cns). * participants with brain metastases are eligible provided that evidence of clinical and radiographic stable disease for at least 4 weeks after definitive therapy is given and participants have not used prohibited levels of steroids for at least 4 weeks prior to first dose of the study. * received prior treatment with ox40 or toll-like receptor (tlr) agonists (excluding topical agents).

Keywords: squamous cell carcinoma head and neck squamous cell carcinoma locally advanced head and neck squamous cell carcinoma metastatic head and neck squamous cell carcinoma cancer
knee arthroplasty pain coping skills training (kastpain): a randomized trial

Conditions: Knee Osteoarthritis

Summary: patients undergoing knee replacement surgery and who have high levels of pain catastrophizing are at risk for poor outcome. the clinical trial is designed to determine if a pain coping skills training intervention delivered by physical therapists and supervised by psychologists is more effective at reducing pain and improving function and is more cost effective than arthritis education or usual care.

approximately 25% of patients following knee arthroplasty have disabling pain following apparently successful surgery. recent research suggests that pain catastrophizing plays a key role in determining which patients with knee arthroplasty have a poor outcome. in addition to this evidence, a substantial literature suggests that pain coping skills training is effective for patients with chronic pain but the intervention has not been studied for surgical patients with severe arthritic knee pain. we designed the knee arthroplasty pain coping skills training (kastpain) trial to address this research need. this phase iii three-arm randomized clinical trial seeks to combine a strong and diverse group of researchers to examine an important and understudied area in the joint arthroplasty literature. the kastpain trial will be the first to examine the utility of a perioperative pain coping intervention for this substantial population of patients.

Eligibility criteria:
inclusion criteria: * adults 45 years and older and capable of providing informed consent * diagnosis of osteoarthritis as determined by participating orthopaedic surgeons * scheduled for an elective unilateral total or unicompartmental knee arthroplasty no sooner than 1 week and no later than 8 weeks from the time of recruitment * score of greater than or = to 16 on the pain catastrophizing scale * score of greater than or = to 5 on the womac pain scale * able to read and speak english exclusion criteria: * scheduled for revision arthroplasty surgery * underwent contralateral knee arthroplasty surgery or hip arthroplasty surgery within 6 months of currently planned surgery * unable to or declines study participation * self-reported diagnosis of rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosis, ankylosing spondylitis * arthroplasty surgery scheduled because of fracture, malignancy or infection * scheduled for bilateral arthroplasty surgery * scheduled to undergo hip or knee arthroplasty within 6 months of current knee arthroplasty * score of 20 or greater on the phq-8 depression scale * score of less than 3 on the six-item cognitive screener

Keywords: arthroplasty pain
fixation of unstable sacral fractures by transpedicular system

Conditions: Fixation; Unstable Sacral Fractures; Transpedicular Sacral Fixation

Summary: this research aimed to assess the role of the transpedicular fixation system in the management of unstable sacral fractures in adults.

pelvic ring disruptions are high-energy injuries with a significant impact on quality of life and higher levels of mortality. unstable sacral fracture is an unusual injury, and even though many studies implicate the surgical intervention as the treatment of choice, the purposes of surgery on sacral fractures include pelvic ring reconstruction, lumbopelvic stability restoration, fracture healing, early mobilization, fracture displacement prevention and improving the neurological deficiency. more and more surgeons are advocating for surgical management in the treatment of sacral fractures, and open reduction internal fixation (orif) has demonstrated marked benefits over conservative treatment.

Eligibility criteria:
inclusion criteria: * adult patients over 18 years old age. * both sexes. * unstable ao sacral fracture type b and type c. * patient fit for surgery and hemodynamic stable patient. * closed fracture. exclusion criteria: * ao sacral fracture type a. * bedridden before the trauma. * patient unfit for surgery. * open sacral fractures. * sacral fractures with massive morel-lavallee lesions.
a study to test the effect of gw786034 (pazopanib) on p450 enzymes

Conditions: Carcinoma, Renal Cell

Summary: this is a phase i study to determine the effect of gw786034 (pazopanib) on p450 enzymes. this study will help determine which types of drugs may interact with gw786034.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of advanced solid tumors. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * adequate bone marrow, renal, lung, and liver function. * a female subject must not be pregnant and will agree not to become pregnant during the trial exclusion criteria: * any major surgery, chemotherapy, hormone therapy, investigational drugs, or radiotherapy within the last 28 days. * poorly controlled hypertension. * corrected qt (qtc) prolongation defined as a qtc interval greater than or equal to 480 msec and a prior history of cardiovascular disease, arrhythmias, or significant ecg abnormalities. * arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within the last 3 months. * current use of therapeutic anticoagulation (low molecular weight heparin, oral anticoagulant agents). amiodarone must not have been taken for at least 6 months prior to the administration of the first dose of study drug. * history of brain metastases. * has narrow-angle glaucoma which is a contraindication to midazolam use. * history of nicotine-containing product (including cigarettes, cigars, nicotine patches) use within the past 6 months. * a history of bleeding problems.

Keywords: gw786034 (pazopanib) cytochrome p450 interaction
an observational study of patients receiving t-dxd for treatment of her2+, and her2-low unresectable and/or metastatic breast cancer

Conditions: Breast Cancer

Summary: this study will collect real-world clinical and patient reported outcomes (pro) and diary data from eligible patients with documented human epidermal growth factor receptor 2 (her2+) \[globally\] or her2-low \[north america only\] in routine clinical practice.

this is a multi-center, observational prospective study that will characterize the demographic and clinical characteristics, treatment patterns, effectiveness, tolerability and its management, and patient experience of trastuzumab deruxtecan (t-dxd) in a real-world setting. this study is planned to be conducted in several countries and aims to enroll approximately 750 patients eligible patients with her2+ unresectable and/or metastatic breast cancer (mbc) who has received a prior anti her2 based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and has developed disease recurrence during or within 6 months of completing therapy. approximately 250 eligible patients with her2-low unresectable and/or mbc who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy will be enrolled into the study in north america only. the planned duration of patient recruitment is approximately 18 months for her2+ and approximately 12 months for her2 low.

Eligibility criteria:
inclusion criteria: * patients ≥18 years of age at time of consent. * histological or cytological confirmed diagnosis of unresectable and/or mbc. * documented her2 status via a validated method. * adult patients with unresectable or metastatic her2+ breast cancer who have received a prior anti-her2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing therapy. or adult patients with unresectable or metastatic her2 low (ihc 1+ or ihc 2+/ish-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. * decision to newly initiate monotherapy t-dxd per standard of care. * capable of providing informed consent and completing questionnaires. exclusion criteria: * pregnancy or breastfeeding. * history of other primary malignancies in 2 years prior to unresectable and/or mbc diagnosis. * patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded.

Keywords: real-world evidence unresectable breast cancer metastatic breast cancer her2+ her2-low observational non-interventional